FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment - FINCHANNEL
The first FDA-approved antisense oligonucleotide for hepatitis B may let some patients stop long-term antiviral therapy, officials said.
10 Articles
10 Articles
Times of India
BizTocUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Hibsago, GSK's new hepatitis B treatment, recently secured approval from the US FDA, allowing patients to better manage their condition after therapy. This approval is vital as GSK aims for annual revenues of over £40 billion by 2031. The drug is already approved in Japan and is being assessed in China and Europe. Collaboration with Ionis Pharmaceuticals means they will receive milestone payments.
US FDA approves GSK’s hepatitis B drug, offering patients chance to stop long-term treatment - Regional Media News
Oct 20 (Reuters) - The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing patients with the liver infection a way to keep the virus under control after stopping treatment. The drug, chemically known as bepirovirsen, is the [...]
US approves new hepatitis B treatment - tennews.in: National News Portal
Washington, Oct 21 (IANS) The United States has approved a new treatment for chronic hepatitis B that could allow some patients to stop taking antiviral medicines while maintaining control over the virus. The US Food and Drug Administration (FDA) announced Tuesday that it had approved Hibsago (bepirovirsen), an injectable medicine developed by GSK, for certain […] The post US approves new hepatitis B treatment appeared first on tennews.in: Natio…
Washington, Oct 21 (IANS) The US has approved a new treatment for chronic hepatitis B. This will allow some patients to stop taking their antiviral medications while keeping the virus under control. The US Food and Drug Administration (FDA) announced on Tuesday that it has approved Hibsago (bepirovirsen), an injectable drug developed by GSK, for adults with chronic hepatitis B who do not have cirrhosis. This treatment is the first antisense olig…
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
